Top

Published in:

Open Access 01-12-2019 | Commentary

Practical tools to identify short children born small-for-gestational-age eligible for rhGH treatment according to Italian regulation

Authors: Gianluca Tornese, Flavia Pricci, Maria Chiara Pellegrin, Marika Villa, Daniela Rotondi, Elvira Agazio, Egidio Barbi

Published in: Italian Journal of Pediatrics | Issue 1/2019

Abstract

Recombinant human growth hormone (rhGH) is an approved and effective treatment for short children born small for gestational age (SGA). Prevalence of children eligible for treatment as SGA is reported to be 1:1800. The latest data from the National Registry of Growth Hormone therapy (RNAOC) showed that the number of children treated with SGA indication is still small (prevalence 0.37/100,000) and these children are significantly less reported than those treated for growth hormone deficiency (GHD), although GHD prevalence is 1:4000–1:10,000. This means that many short children born SGA are still not properly identified, and therefore not treated with rhGH, or misdiagnosed as GHD. This article provides some practical tools for the identification of children eligible for rhGH treatment.

Fujita K, Nagasaka M, Iwatani S, et al. Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age: population-based study. Pediatr Int. 2016;58:372–6.CrossRef

Albertsson-Wikland K, Karlberg J. Postnatal growth of children born small for gestational age. Acta Paediatr Suppl. 1997;423:193–5.CrossRef

Leger J, Limoni C, Czernichow P, et al. Prediction of the outcome of growth at 2 years of age in neonates with intra-uterine growth retardation. Early Hum Dev. 1997;48:211–23.CrossRef

Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24–October 1, 2001. Pediatrics. 2003;111:1253–61.CrossRef

Maiorana A, Cianfarani S. Impact of TH therapy on adult height of children born small for gestational age. Pediatrics. 2009;124:e519–31.CrossRef

de Zegher F, Francois I, van Helvoirt M, et al. Growth hormone treatment of short children born small for gestational age. Trends Endocrinol Metab. 1998;9(6):233–7.CrossRef

Italia. Determinazione dell’Agenzia Italiana del Farmaco 19 giugno 2014. Modifica alla Nota AIFA 39. Gazzetta Ufficiale. Serie Generale n. 154 del 5 luglio 2014.

Bertino E, Spada E, Occhi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr. 2010;51:353–61.PubMed

Pricci F, Villa M, Maccari F, et al. The Italian registry of GH treatment: electronic clinical report form (e-CRF) and web-based platform for the national database of GH prescriptions. J Endocrinol Investig. 2018;42:769–77 [Epub ahead of print].CrossRef

10.

Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Investig. 2006;29:581–93.CrossRef

11.

WHO Multicentre Growth Reference Study Group. WHO child growth standards based on length/height, weight and age. Acta Paediatr. 2006;450(Suppl 450):76–85.

Title: Practical tools to identify short children born small-for-gestational-age eligible for rhGH treatment according to Italian regulation
Authors: Gianluca Tornese
Flavia Pricci
Maria Chiara Pellegrin
Marika Villa
Daniela Rotondi
Elvira Agazio
Egidio Barbi
Publication date: 01-12-2019
Publisher: BioMed Central
Published in: Italian Journal of Pediatrics / Issue 1/2019
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-019-0715-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Practical tools to identify short children born small-for-gestational-age eligible for rhGH treatment according to Italian regulation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Cortisol, leptin and free leptin index (FLI) in newborns in the first days of life and their importance for body weight programming

Report on advances for pediatricians in 2018: allergy, cardiology, critical care, endocrinology, hereditary metabolic diseases, gastroenterology, infectious diseases, neonatology, nutrition, respiratory tract disorders and surgery

Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry

The impact of IGF-I, puberty and obesity on early retinopathy in children: a cross-sectional study

Authors’ reply - anaphylactic shock with methylprednisolone, Kounis syndrome and Hypersitivity to corticosteroids: a clinical paradox

Symptomatic malignant spinal cord compression in children: a single-center experience